Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A.

J Clin Oncol. 2010 May 10;28(14):2339-47. doi: 10.1200/JCO.2009.25.1983. Epub 2010 Apr 12.

PMID:
20385996
2.

'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'.

Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G, Pieters R, Pui CH.

Leukemia. 2010 Feb;24(2):253-4. doi: 10.1038/leu.2009.276. No abstract available.

PMID:
20145664
3.

Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.

Krishnan S, Wade R, Moorman AV, Mitchell C, Kinsey SE, Eden TO, Parker C, Vora A, Richards S, Saha V.

Leukemia. 2010 Feb;24(2):450-9. doi: 10.1038/leu.2009.264. Epub 2009 Dec 17.

4.

Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response.

Cao C, Han Y, Ren Y, Wang Y.

Cell Mol Immunol. 2009 Dec;6(6):469-75. doi: 10.1038/cmi.2009.59.

5.

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML.

J Clin Oncol. 2010 Feb 1;28(4):648-54. doi: 10.1200/JCO.2009.22.2950. Epub 2009 Oct 19.

6.

Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response.

Karl S, Pritschow Y, Volcic M, Häcker S, Baumann B, Wiesmüller L, Debatin KM, Fulda S.

J Cell Mol Med. 2009 Oct;13(10):4239-56. doi: 10.1111/j.1582-4934.2009.00888.x. Epub 2009 Sep 1.

7.

Relapsed acute lymphoblastic leukemia: current status and future opportunities.

Harned TM, Gaynon P.

Curr Oncol Rep. 2008 Nov;10(6):453-8. Review.

PMID:
18928659
8.

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].

Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL.

J Clin Oncol. 2008 Aug 20;26(24):3971-8. doi: 10.1200/JCO.2008.16.1414. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697..

9.

Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children's Oncology Group..

J Clin Oncol. 2007 Dec 20;25(36):5800-7.

PMID:
18089878
10.

High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.

von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G; ALL-REZ BFM Study Group..

Blood. 2008 Mar 1;111(5):2573-80. Epub 2007 Dec 18.

11.

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA Jr, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon PS.

Blood. 2008 Mar 1;111(5):2548-55. Epub 2007 Nov 26.

12.

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.

Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ.

Leukemia. 2005 Dec;19(12):2130-8.

PMID:
16304572
13.

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig WD, Henze G.

J Clin Oncol. 2005 Nov 1;23(31):7942-50. Erratum in: J Clin Oncol. 2008 May 1;26(13):2238.

PMID:
16258094
14.

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.

Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, Saha V.

Br J Haematol. 2005 Jul;130(1):67-75.

PMID:
15982346
15.

Surrogate endpoints and FDA's accelerated approval process.

Fleming TR.

Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78.

16.

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

Chan A, Weilbach FX, Toyka KV, Gold R.

Clin Exp Immunol. 2005 Jan;139(1):152-8.

17.

Accelerated approval seen as triumph and roadblock for cancer drugs.

Susman E.

J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6. No abstract available.

PMID:
15494596
18.

A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences.

Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR.

J Biol Chem. 2004 Apr 30;279(18):18814-23. Epub 2004 Feb 12.

19.

Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA.

Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62. Epub 2003 Sep 23.

PMID:
14504921
20.

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P.

Semin Radiat Oncol. 2003 Jul;13(3):176-81. Review.

PMID:
12903007

Supplemental Content

Support Center